Drug
NAD+
NAD+ is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_3
Combination Gerotherapeutic Interventions for Healthspan Improvement
NCT07475546
recruitingnot_applicable
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
completedphase_2
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
NCT04604704
Clinical Trials (3)
Showing 3 of 3 trials
NCT07475546Phase 3
Combination Gerotherapeutic Interventions for Healthspan Improvement
NCT06919328Not Applicable
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT04604704Phase 2
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3